Table 3.
Univariable analysis of preoperative candidate predictors for pancreatic fistula in 266 patients undergoing distal pancreatectomy in development cohort (Helsinki University Hospital)
| OR | P | |
|---|---|---|
| Male sex | 0.82 (0.44, 1.54) | 0.550 |
| Smoker | 1.60 (0.84, 3.04) | 0.140 |
| Diabetes mellitus | 0.35 (0.13, 0.93) | 0.034 |
| Neoadjuvant therapy | 0.55 (0.19, 1.65) | 0.290 |
| Sarcopenia* | 0.76 (0.35, 1.62) | 0.470 |
| Serrated pancreatic parenchyma | 1.64 (0.87, 3.10) | 0.130 |
| Transection at pancreatic neck | 0.50 (0.27, 0.93) | 0.027 |
| Age (years) | 0.98 (0.95, 0.99)† | 0.016 |
| BMI (kg/m2) | 1.06 (0.99, 1.13)† | 0.064 |
| Charlson Co-morbidity Index score | 0.93 (0.81, 1.06)† | 0.280 |
| PT at pancreatic neck (mm) | 1.15 (1.05, 1.24)† | 0.001 |
| PT at transection site (mm) | 1.51 (1.35, 1.68)† | <0.001 |
| MPDD at pancreatic neck (mm) | 0.97 (0.75, 1.25)† | 0.790 |
| MPDD at transection site (mm) | 0.68 (0.47, 0.98)† | 0.038 |
| Perirenal fat pad thickness (mm) | 0.99 (0.97, 1.02)† | 0.640 |
Values in parentheses are 95 per cent confidence intervals.
*
Defined as psoas muscle thickness per height in the lowest quartile.
†
Per unit increase. PT; pancreatic thickness, MPDD; main pancreatic duct diameter.